1333489-03-4
1333489-03-4
Chemical Structure
Regorafénib N-oxyde-d3(M2)
- CAS No.: 1333489-03-4
- Formula:C21H12D3ClF4N4O4
- Molecular Weight:501.83
IUPAC Name: 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl)ureido)-3-fluorophenoxy)-2-((methyl-d3)carbamoyl)pyridine 1-oxide
InChIKey: NUCXNEKIESREQY-FIBGUPNXSA-N
SMILES: [2H]C([2H])([2H])NC(C1=CC(OC2=CC(F)=C(C=C2)NC(NC3=CC(C(F)(F)F)=C(C=C3)Cl)=O)=CC=[N+]1[O-])=O
Biological Activity: Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2[1]. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively[2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Regorafénib N-oxyde-d3(M2) | Regorafénib N-oxyde-d3(M2) is the deuterium labeled Regorafénib N-oxyde M2. Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafénib N-oxyde (M2) (Standard) | ≥98% | Quinocetone (Standard) is the analytical standard of Quinocetone. This product is intended for research and analytical applications. Quinocetone is a potent synthetic antimicrobial agent that is used for improving the feed efficiency and controlling dysentery in food-producing animals. |
||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafénib N-oxyde (M2)-13C,d3 | Regorafénib N-oxyde (M2)-13C,d3 is the 13C- and deuterium labeled Regorafénib N-oxyde (M2). Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Regorafénib N-oxyde (M2) | 98.15% | Regorafénib N-oxyde M2 is an active metabolite of Regorafenib. Regorafenib is a multi-target inhibitor for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1 with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. Allard M, et al. Simultaneous analysis of regorafenib and sorafenib and three of their metabolites in human plasma using LC-MS/MS. J Pharm Biomed Anal. 2017 Aug 5;142:42-48. [Content Brief]
